MX2023004668A - Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico. - Google Patents

Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico.

Info

Publication number
MX2023004668A
MX2023004668A MX2023004668A MX2023004668A MX2023004668A MX 2023004668 A MX2023004668 A MX 2023004668A MX 2023004668 A MX2023004668 A MX 2023004668A MX 2023004668 A MX2023004668 A MX 2023004668A MX 2023004668 A MX2023004668 A MX 2023004668A
Authority
MX
Mexico
Prior art keywords
crystal
compound
diffraction
cukî
radiation
Prior art date
Application number
MX2023004668A
Other languages
English (en)
Inventor
Toshio Fujiwara
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MX2023004668A publication Critical patent/MX2023004668A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Steroid Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)

Abstract

Un objeto principal de la presente invención consiste en proporcionar un nuevo cristal de ácido 2-{4-[N-(5,6-difenilpirazin -2-il)-N-isopropilamino]butiloxi}acético (de ahora en más en la presente, mencionado como "compuesto B"). Un cristal de la forma I de compuesto B, que muestra picos en ángulos de difracción (2?) de 6,4?, 8,1?, 9,5?, 10,9?, 13,2?, 15,7?, 17,0?, 19,5?, 20,3?, 21,0? y 22,8? en un espectro de difracción de polvos por rayos X obtenido usando una radiación Cu-Ka (?=1,54 Å). Un cristal de la forma II de compuesto B, que muestra picos en ángulos de difracción (2?) de 9,6?, 11,4?, 11,7?, 16,3?, 17,5?, 18,5?, 18,7?, 19,9?, 20,1?, 21,0? y 24,6? en un espectro de difracción de polvos por rayos X obtenido usando una radiación Cu-Ka (?=1,54 Å).
MX2023004668A 2017-09-28 2020-07-13 Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico. MX2023004668A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017187296 2017-09-28

Publications (1)

Publication Number Publication Date
MX2023004668A true MX2023004668A (es) 2023-05-19

Family

ID=65902864

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020007315A MX2020007315A (es) 2017-09-28 2018-09-27 Cristal.
MX2023004668A MX2023004668A (es) 2017-09-28 2020-07-13 Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020007315A MX2020007315A (es) 2017-09-28 2018-09-27 Cristal.

Country Status (18)

Country Link
US (3) US10906879B2 (es)
EP (2) EP3689854A4 (es)
JP (3) JP7160043B2 (es)
KR (2) KR102675320B1 (es)
CN (2) CN111263754A (es)
AR (1) AR112842A1 (es)
AU (2) AU2018338856B2 (es)
BR (1) BR112020005428A2 (es)
CA (1) CA3076877A1 (es)
CO (1) CO2020003424A2 (es)
IL (1) IL273430A (es)
MX (2) MX2020007315A (es)
PH (1) PH12020550149A1 (es)
RU (1) RU2020112117A (es)
SG (1) SG11202002443QA (es)
TW (2) TWI801421B (es)
UA (1) UA126928C2 (es)
WO (1) WO2019065792A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI801421B (zh) * 2017-09-28 2023-05-11 日商日本新藥股份有限公司 結晶
WO2021023271A1 (zh) * 2019-08-06 2021-02-11 南京明德新药研发有限公司 作为前列环素受体激动剂的化合物的晶型及其制备方法
TW202114998A (zh) * 2019-08-19 2021-04-16 日商日本新藥股份有限公司 鹽

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI316055B (es) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
DK2246336T3 (da) 2008-02-28 2020-07-20 Nippon Shinyaku Co Ltd Fibroseinhibitor
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
CN102065864B (zh) 2008-06-23 2012-11-21 日本新药株式会社 炎性肠病治疗剂
WO2009157396A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 脊柱管狭窄症治療剤
MY163762A (en) 2008-07-23 2017-10-31 Toray Industries Therapeutic agent for chronic renal failure
KR102705198B1 (ko) * 2009-06-26 2024-09-11 니뽄 신야쿠 가부시키가이샤 결정
CN106279047B (zh) * 2015-05-13 2019-05-03 普济生物科技（台州）有限公司 一种前列环素受体激动剂的制备方法
WO2017042828A2 (en) * 2015-09-10 2017-03-16 Megafine Pharma (P) Ltd. Process for the preparation of selexipag and intermediates thereof
WO2017060827A1 (en) 2015-10-07 2017-04-13 Lupin Limited An imrpoved process for the preparation of selexipag or its pharmaceutically acceptable salts
EP3481807A4 (en) * 2016-07-05 2020-01-15 Maithri Drugs Private Limited NEW PROCESS FOR THE PREPARATION OF 2- {4 - [(5,6-DIPHENYL PYRAZIN-2-YL) (ISOPROPYL) AMINO] BUTOXY} -N- (METHYLSULFONYL) ACETAMIDE AND NEW POLYMORPHS THEREOF
CN106957269A (zh) * 2016-12-21 2017-07-18 南京艾德凯腾生物医药有限责任公司 一种成人肺动脉高压治疗药物赛乐西帕的制备方法
CN107365275B (zh) * 2017-06-14 2020-07-03 杭州华东医药集团新药研究院有限公司 高纯度的赛乐西帕
TWI801421B (zh) * 2017-09-28 2023-05-11 日商日本新藥股份有限公司 結晶

Also Published As

Publication number Publication date
US10906879B2 (en) 2021-02-02
TWI834536B (zh) 2024-03-01
EP3689854A4 (en) 2021-06-09
IL273430A (en) 2020-05-31
EP3689854A1 (en) 2020-08-05
PH12020550149A1 (en) 2021-02-08
EP4371617A3 (en) 2024-08-07
BR112020005428A2 (pt) 2020-09-29
UA126928C2 (uk) 2023-02-22
KR102675320B1 (ko) 2024-06-14
TW202332673A (zh) 2023-08-16
AU2018338856B2 (en) 2023-09-21
JP2024045685A (ja) 2024-04-02
US20210114995A1 (en) 2021-04-22
JPWO2019065792A1 (ja) 2020-10-22
JP7160043B2 (ja) 2022-10-25
CO2020003424A2 (es) 2020-06-19
AR112842A1 (es) 2019-12-18
CA3076877A1 (en) 2019-04-04
CN111263754A (zh) 2020-06-09
US20200223804A1 (en) 2020-07-16
US11655218B2 (en) 2023-05-23
JP7485738B2 (ja) 2024-05-16
TW201920121A (zh) 2019-06-01
CN117510418A (zh) 2024-02-06
MX2020007315A (es) 2020-08-20
SG11202002443QA (en) 2020-04-29
JP2022173401A (ja) 2022-11-18
AU2018338856A1 (en) 2020-04-16
KR20200060393A (ko) 2020-05-29
KR20240042215A (ko) 2024-04-01
EP4371617A2 (en) 2024-05-22
US20230303500A1 (en) 2023-09-28
AU2023274142A1 (en) 2023-12-21
TWI801421B (zh) 2023-05-11
RU2020112117A (ru) 2021-10-28
WO2019065792A1 (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
MX2023004668A (es) Forma cristalina de acido 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isop ropilamino]butiloxi}acetico.
WO2019191229A8 (en) Compounds for treating huntington's disease
PH12018501226A1 (en) Methods for treating huntingtons disease
CY1120855T1 (el) Αρωματικη ενωση
MY186531A (en) Crystals
CY1120173T1 (el) Ενωση πυραζολο-αμιδιου και φαρμακευτικες χρησεις αυτης
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
EA201590475A1 (ru) Тетрациклиновые соединения
BR112016027760A2 (pt) método de síntese de ph baixo de complexo de zinco-lisina
SG11201809127PA (en) Crystalline polymorph of 15b-hydroxy-osaterone acetate
MX2018013764A (es) Cristal de derivado de quinolina.
WO2015017378A3 (en) Novel copper-cysteamine and methods of use
GB201020397D0 (en) Compounds
MX2017003607A (es) Sales de clorhidrato de aluminio que exhiben un pico 1 sec alto.
MX2023005387A (es) Cristales de maleato de forma-ii de (s)-n2-[1-(4-fluorofenil)etil] -4-(1-metil-1h-pirazol-4-il)-n6-(pirazin-2-il)piridina-2,6-diamin a.
WO2011160821A3 (en) Organic salts and co-crystals of phenylbutyric acid
RU2013149318A (ru) Наномодифицированный эпоксидный сферопластик
RU2010130104A (ru) 2-(1'-гидрокси-4'-изопропилен-1'-метилциклогексил-2'-тио)-метилэтаноат, обладающий фунгицидным и противовоспалительным действием
EA201690622A1 (ru) Соль дигидрофосфат тенофовира дизопроксила
MX2016008529A (es) Cristales (2) de compuesto de pirazino[2,1-c][1,2,4]triazina.
EA201400269A1 (ru) Способ синтеза соединений 7,8-диметокси -1,3-дигидро-2h-3-бензазепин-2-она и применение в синтезе ивабрадина
EA201691559A1 (ru) Твердая форма тапентадола малеата и способ его получения
MX2020007656A (es) Forma cristalina de particulas sólidas de cocristal de apomorfina·ácido palmítico.
RU2012131439A (ru) Гербицидная композиция в виде водно-диспергируемых гранул
UA108849C2 (xx) Кристалічна форма 2-{4-[n-(5,6-дифенілпіразин-2-іл)-n-ізопропіламіно]бутилокси}-n-(метилсульфоніл)ацетаміду